Influence of Physiological Variables and Comorbidities on Plasma Aβ40, Aβ42, and p-tau181 Levels in Cognitively Unimpaired Individuals

被引:7
|
作者
Martinez-Dubarbie, Francisco [1 ,2 ]
Guerra-Ruiz, Armando [3 ]
Lopez-Garcia, Sara [1 ,2 ]
Irure-Ventura, Juan [2 ,4 ]
Lage, Carmen [1 ,2 ,5 ]
Fernandez-Matarrubia, Marta [1 ,2 ]
Pozueta-Cantudo, Ana [1 ,2 ]
Garcia-Martinez, Maria [1 ,2 ]
Corrales-Pardo, Andrea [1 ,2 ,6 ]
Bravo, Maria [1 ,2 ]
Martin-Arroyo, Juan [1 ]
Infante, Jon [1 ,2 ,7 ,8 ]
Lopez-Hoyos, Marcos [2 ,4 ,9 ]
Garcia-Unzueta, Maria Teresa [2 ,3 ]
Sanchez-Juan, Pascual [7 ,10 ]
Rodriguez-Rodriguez, Eloy [1 ,2 ,7 ,8 ]
机构
[1] Marques de Valdecilla Univ Hosp, Neurol Serv, Santander 39008, Spain
[2] Inst Res Marques Valdecilla IDIVAL, Santander 39011, Spain
[3] Marques de Valdecilla Univ Hosp, Biochem & Clin Anal Dept, Santander 39008, Spain
[4] Marques de Valdecilla Univ Hosp, Immunol Dept, Santander 39008, Spain
[5] Univ Calif San Francisco, Global Brain Hlth Inst, Equ Brain Hlth, San Francisco, CA 94143 USA
[6] Univ Europea Atlantico, Hlth Sci Dept, Santander 39011, Spain
[7] Network Ctr Biomed Res Neurodegenerat Dis CIBERNED, Madrid 28220, Spain
[8] Univ Cantabria, Med & Psychiat Dept, Santander 39011, Spain
[9] Univ Cantabria, Mol Biol Dept, Santander 39011, Spain
[10] CIEN Fdn, Queen Sofia Fdn Alzheimer Ctr, Madrid 28220, Spain
关键词
Alzheimer's disease; plasma biomarkers; presymptomatic stages; comorbidities; amyloid; tau protein; ALZHEIMER-DISEASE; VALIDATION; BIOMARKERS;
D O I
10.3390/ijms25031481
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Plasma biomarkers for Alzheimer's disease (AD) are a promising tool that may help in early diagnosis. However, their levels may be influenced by physiological parameters and comorbidities that should be considered before they can be used at the population level. For this purpose, we assessed the influences of different comorbidities on AD plasma markers in 208 cognitively unimpaired subjects. We analyzed both plasma and cerebrospinal fluid levels of A beta 40, A beta 42, and p-tau181 using the fully automated Lumipulse platform. The relationships between the different plasma markers and physiological variables were studied using linear regression models. The mean differences in plasma markers according to comorbidity groups were also studied. The glomerular filtration rate showed an influence on plasma A beta 40 and A beta 42 levels but not on the A beta 42/A beta 40 ratio. The amyloid ratio was significantly lower in diabetic and hypertensive subjects, and the mean p-tau181 levels were higher in hypertensive subjects. The glomerular filtration rate may have an inverse relationship on plasma A beta 40 and A beta 42 levels but not on the amyloid ratio, suggesting that the latter is a more stable marker to use in the general population. Cardiovascular risk factors might have a long-term effect on the amyloid ratio and plasma levels of p-tau181.
引用
收藏
页数:17
相关论文
共 30 条
  • [21] Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
    Lussier, Firoza Z.
    Benedet, Andrea L.
    Therriault, Joseph
    Pascoal, Tharick A.
    Tissot, Cecile
    Chamoun, Mira
    Mathotaarachchi, Sulantha
    Savard, Melissa
    Ashton, Nicholas J.
    Karikari, Thomas K.
    Rodriguez, Juan Lantero
    Snellman, Anniina
    Bezgin, Gleb
    Kang, Min Su
    Arias, Jaime Fernandez
    Wang, Yi-Ting
    Gauthier, Serge
    Zetterberg, Henrik
    Blennow, Kaj
    Rosa-Neto, Pedro
    BRAIN COMMUNICATIONS, 2021, 3 (02)
  • [22] APOE ε4 status and plasma p-tau181 interact to influence cognitive performance among non-demented older adults
    Wang, Shanshan
    Ke, Shaofa
    Liu, Suzhi
    Wang, En
    Pan, Tengwei
    NEUROSCIENCE LETTERS, 2023, 796
  • [23] Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease
    Snellman, Anniina
    Ekblad, Laura L.
    Ashton, Nicholas J.
    Karikari, Thomas K.
    Lantero-Rodriguez, Juan
    Pietila, Elina
    Koivumaki, Mikko
    Helin, Semi
    Karrasch, Mira
    Zetterberg, Henrik
    Blennow, Kaj
    Rinne, Juha O.
    NEUROBIOLOGY OF DISEASE, 2023, 183
  • [24] Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease
    Kang, Ju-Hee
    Irwin, David J.
    Chen-Plotkin, Alice S.
    Siderowf, Andrew
    Caspell, Chelsea
    Coffey, Christopher S.
    Waligorska, Teresa
    Taylor, Pegg
    Pan, Sarah
    Frasier, Mark
    Marek, Kenneth
    Kieburtz, Karl
    Jennings, Danna
    Simuni, Tanya
    Tanner, Caroline M.
    Singleton, Andrew
    Toga, Arthur W.
    Chowdhury, Sohini
    Mollenhauer, Brit
    Trojanowski, John Q.
    Shaw, Leslie M.
    JAMA NEUROLOGY, 2013, 70 (10) : 1277 - 1287
  • [25] Neurodegenerative disease biomarkers Aβ1-40, Aβ1-42, tau, and p-tau181 in the vervet monkey cerebrospinal fluid: Relationto normal aging, genetic influences, and cerebral amyloid angiopathy
    Chen, Jason A.
    Fears, Scott C.
    Jasinska, Anna J.
    Huang, Alden
    Al-Sharif, Noor B.
    Scheibel, Kevin E.
    Dyer, Thomas D.
    Fagan, Anne M.
    Blangero, John
    Woods, Roger
    Jorgensen, Matthew J.
    Kaplan, Jay R.
    Freimer, Nelson B.
    Coppola, Giovanni
    BRAIN AND BEHAVIOR, 2018, 8 (02):
  • [26] Findings of 18F-PI-2620 tau PET imaging in patients with Alzheimer's disease and healthy controls in relation to the plasma P-tau181 levels in a Japanese sample
    Bun, Shogyoku
    Moriguchi, Sho
    Tezuka, Toshiki
    Sato, Yoshiaki
    Takahata, Keisuke
    Seki, Morinobu
    Nakajima, Shinichiro
    Yamamoto, Yasuharu
    Sano, Yasunori
    Suzuki, Natsumi
    Morimoto, Ayaka
    Ueda, Ryo
    Tabuchi, Hajime
    Ito, Daisuke
    Mimura, Masaru
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2022, 42 (04) : 437 - 448
  • [27] Electrochemical impedance-based biosensor for label-free determination of plasma P-tau181 levels for clinically accurate diagnosis of mild cognitive impairment and Alzheimer's disease
    Tieu, My-Van
    Choi, Seong Hye
    Le, Hien T. Ngoc
    Cho, Sungbo
    ANALYTICA CHIMICA ACTA, 2023, 1273
  • [28] Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease
    Chong, Joyce R.
    Ashton, Nicholas J.
    Karikari, Thomas K.
    Tanaka, Tomotaka
    Saridin, Francis N.
    Reilhac, Anthonin
    Robins, Edward G.
    Nai, Ying-Hwey
    Vrooman, Henri
    Hilal, Saima
    Zetterberg, Henrik
    Blennow, Kaj
    Lai, Mitchell K. P.
    Chen, Christopher P.
    ALZHEIMERS & DEMENTIA, 2021, 17 (10) : 1649 - 1662
  • [29] Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects (vol 11, 222, 2019)
    Lue, Lih-Fen
    Pai, Ming-Chyi
    Chen, Ta-Fu
    Hu, Chaur-Jong
    Huang, Li-Kai
    Lin, Wei-Che
    Wu, Chau-Chung
    Jeng, Jian-Shing
    Blennow, Kaj
    Sabbagh, Marwan N.
    Yan, Sui-Hing
    Wang, Pei-Ning
    Yang, Shieh-Yueh
    Hatsuta, Hiroyuki
    Morimoto, Satoru
    Takeda, Akitoshi
    Itoh, Yoshiaki
    Liu, Jun
    Xie, Haiqun
    Chiu, Ming-Jang
    FRONTIERS IN AGING NEUROSCIENCE, 2019, 11
  • [30] Plasma Aβ42/Aβ40 and p-tau 181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment
    Xiao, Zhenxu
    Wu, Wanqing
    Ma, Xiaoxi
    Liang, Xiaoniu
    Lu, Jiaying
    Zheng, Li
    Ding, Saineng
    Lei, Qiqi
    Luo, Jianfeng
    Chen, Keliang
    Ding, Ding
    Zhao, Qianhua
    CLINICAL CHEMISTRY, 2022, 68 (12) : 1552 - 1563